Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Histogen Inc | HSTO | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.0% | 1.18 | 04:00:04 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.18 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.7603 - 9.40 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 1.18 | USD |
Histogen Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 5.04M | 4.27M | 4.15M | $ 3.77M | $ - | -3.37 | 7.80 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 106.79k | 1.40% |
Histogen News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical HSTO Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.9957 | 1.6201 | 0.8329 | 1.33 | 11,331,119 | 0.1843 | 18.51% |
| 1 Month | 1.07 | 1.6201 | 0.8329 | 1.33 | 2,730,551 | 0.11 | 10.28% |
| 3 Months | 0.77 | 1.6201 | 0.77 | 1.31 | 1,037,817 | 0.41 | 53.25% |
| 6 Months | 1.34 | 1.64 | 0.7603 | 1.28 | 570,878 | -0.16 | -11.94% |
| 1 Year | 5.50 | 9.40 | 0.7603 | 4.53 | 1,244,039 | -4.32 | -78.55% |
| 3 Years | 88.20 | 100.00 | 0.7603 | 15.36 | 1,178,460 | -87.02 | -98.66% |
| 5 Years | 88.20 | 100.00 | 0.7603 | 15.36 | 1,178,460 | -87.02 | -98.66% |
Histogen Description
| Histogen Inc is a clinical-stage therapeutics company focused on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products as potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. Under its biologics technology platform, the product candidates in development are HST-003, a treatment for joint cartilage repair, and HST-004, a treatment for spinal disc repair. It also has a pipeline of clinical and preclinical small molecule pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases that the company intends to develop. |